- Home
- MRCO vs PLX Comparison
MRCO vs PLX Comparison
Compare MRCO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCO | PLX |
|---|---|---|
| Founded | 2025 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.8M | 182.9M |
| IPO Year | 2026 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MRCO | PLX |
|---|---|---|
| Price | $9.86 | $2.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.2K | ★ 770.8K |
| Earning Date | N/A | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.22 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.85 | $1.60 |
| 52 Week High | $10.03 | $3.19 |
Technical Indicators
Market Signals| Indicator | MRCO | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 59.55 |
| Support Level | $9.86 | $2.59 |
| Resistance Level | $9.90 | $2.85 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 5.56 | 72.14 |
Price Performance
Historical ComparisonAbout MRCO Mercator Acquisition Corp. Class A Ordinary Shares
Mercator Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.